Ryo Oikawa
University of Tokyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ryo Oikawa.
Proceedings of the National Academy of Sciences of the United States of America | 2006
Taka-aki Koshimizu; Yoshihisa Nasa; Akito Tanoue; Ryo Oikawa; Yuji Kawahara; Yasushi Kiyono; Tetsuya Adachi; Toshiki Tanaka; Tomoyuki Kuwaki; Toyoki Mori; Satoshi Takeo; Hitoshi Okamura; Gozoh Tsujimoto
Arginine-vasopressin (AVP) is a hormone that is essential for both osmotic and cardiovascular homeostasis, and exerts important physiological regulation through three distinct receptors, V1a, V1b, and V2. Although AVP is used clinically as a potent vasoconstrictor (V1a receptor-mediated) in patients with circulatory shock, the physiological role of vasopressin V1a receptors in blood pressure (BP) homeostasis is ill-defined. In this study, we investigated the functional roles of the V1a receptor in cardiovascular homeostasis using gene targeting. The basal BP of conscious mutant mice lacking the V1a receptor gene (V1a−/−) was significantly (P < 0.001) lower compared to the wild-type mice (V1a+/+) without a notable change in heart rate. There was no significant alteration in cardiac functions as assessed by echocardiogram in the mutant mice. AVP-induced vasopressor responses were abolished in the mutant mice; rather, AVP caused a decrease in BP, which occurred in part through V2 receptor-mediated release of nitric oxide from the vascular endothelium. Arterial baroreceptor reflexes were markedly impaired in mutant mice, consistent with a loss of V1a receptors in the central area of baroreflex control. Notably, mutant mice showed a significant 9% reduction in circulating blood volume. Furthermore, mutant mice had normal plasma AVP levels and a normal AVP secretory response, but had significantly lower adrenocortical responsiveness to adrenocorticotropic hormone. Taken together, these results indicate that the V1a receptor plays an important role in normal resting arterial BP regulation mainly by its regulation of circulating blood volume and baroreflex sensitivity.
Cardiovascular Research | 2003
Hiroyuki Yoshida; Masaya Takahashi; Miki Koshimizu; Kouichi Tanonaka; Ryo Oikawa; Teruhiko Toyo-oka; Satoshi Takeo
OBJECTIVE Genetic defects in several sarcoglycans (SGs) and dystrophin (Dys) play a critical role in cardiomyopathy. The present study was designed to determine whether changes in SGs and Dys might occur in animals with chronic heart failure (CHF) induced by acute myocardial infarction (AMI), which have no genetic defects. METHODS AMI was induced by the left coronary artery ligation (CAL) in rats. The hemodynamic parameters of the 2- and 8-week CAL (2w- and 8w-CAL) rats were measured and the myocardial SGs, Dys, calpain, and calpastatin levels were determined by the Western blot method. Myocardial calpain-like protease activity was evaluated as caseinolysis activity. RESULTS Increases in left ventricular end-diastolic pressure (LVEDP) and right ventricular systolic pressure, and a decrease in +/-dP/dt were observed at the 2nd week, whereas cardiac output index (COI) was preserved. In contrast, the 8w-CAL rats showed a further increment in LVEDP with low COI. alpha-SG of the viable left ventricle (LV), and septum (Sep) of the 8w-CAL rat decreased (60-70% of the control). The alpha- and beta-SGs of the right ventricle (RV) of the 2w- and 8w-CAL rats were reduced, while gamma- and delta-SGs in the three regions did not change significantly. Dys in the viable LV and RV of the 8w-CAL rat decreased (75% of the control). The amount of m-calpain in the three regions of the 2w- and 8w-CAL rats increased (140-200% of the control), whereas the endogenous calpain inhibitor, calpastatin, did not change significantly. The in vitro degradation studies using purified m-calpain or cytosolic fractions of the 8w-CAL rat heart suggested a reduction in SGs and Dys by calpain. CONCLUSION The results suggest that a decrease in SGs and Dys may play an important role in the pathophysiology of CHF following AMI.
Molecular and Cellular Biochemistry | 2004
Kouichi Tanonaka; Wakako Toga; Masaya Takahashi; Hiroyuki Yoshida; Ryo Oikawa; Satoshi Takeo
Induction of heat shock protein (Hsp) 72 in the right ventricular muscle of the rat with heart failure following acute myocardial infarction (AMI) was examined. AMI was induced by the left coronary artery ligation (CAL). The animals at the 8th, but not 2nd, week after CAL revealed a decrease in cardiac output index (COI), suggesting that heart failure had developed by 8 weeks after CAL. Increases in the right ventricular developed pressure and the ratios of right ventricle/body weight and lung/body weight at the 2nd and 8th weeks showed the development of the right ventricular hypertrophy. After measurement of hemodynamic parameters, the hearts isolated from animals at the 2nd and 8th weeks after CAL (2w- and 8w-CAL hearts, respectively) were perfused and subjected to heat shock (at 42°C, for 15 min) followed by 6-h perfusion. At the end of perfusion, Hsp72 content in the left ventricle without infarct area (viable LV) and the right ventricle (RV) was determined by the Western immunoblotting method. The production of myocardial Hsp72 in the viable LV and RV of the 2w-CAL heart increased after an exposure to heat shock. In contrast, induction of Hsp72 in the viable LV and RV of the 8w-CAL heart was blunted. The results suggest that the development of heart failure following AMI may result in a decrease in the ability for Hsp72 induction not only in the viable LV but also in the RV, leading to contractile dysfunction of the heart.
Journal of Pharmacological Sciences | 2005
Yuji Kawahara; Kouichi Tanonaka; Takuya Daicho; Mikio Nawa; Ryo Oikawa; Yoshihisa Nasa; Satoshi Takeo
Molecular Pharmacology | 2004
Chihiro Hosoda; Taka-aki Koshimizu; Akito Tanoue; Yoshihisa Nasa; Ryo Oikawa; Takashi Tomabechi; Shinya Fukuda; Hitomi Shinoura; Sayuri Oshikawa; Satoshi Takeo; Tadaichi Kitamura; Susanna Cotecchia; Gozoh Tsujimoto
European Journal of Pharmacology | 2007
Masami Hiroyama; Shuyi Wang; Toshinori Aoyagi; Ryo Oikawa; Atsushi Sanbe; Satoshi Takeo; Akito Tanoue
Journal of Cardiovascular Pharmacology | 2006
Masaya Takahashi; Kouichi Tanonaka; Hiroyuki Yoshida; Miki Koshimizu; Takuya Daicho; Ryo Oikawa; Satoshi Takeo
Cardiovascular Research | 2005
Masaya Takahashi; Kouichi Tanonaka; Hiroyuki Yoshida; Ryo Oikawa; Miki Koshimizu; Takuya Daicho; Teruhiko Toyo-oka; Satoshi Takeo
European Journal of Pharmacology | 2007
Ryo Oikawa; Yoshihisa Nasa; Rie Ishii; Tomoyuki Kuwaki; Akito Tanoue; Gozoh Tsujimoto; Satoshi Takeo
European Journal of Pharmacology | 2005
Masaya Takahashi; Kouichi Tanonaka; Hiroyuki Yoshida; Miki Koshimizu; Ryo Oikawa; Takuya Daicho; Satoshi Takeo